See more : Trellus Health plc (TRLS.L) Income Statement Analysis – Financial Results
Complete financial analysis of Monte Rosa Therapeutics, Inc. (GLUE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Monte Rosa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- The York Water Company (YORW) Income Statement Analysis – Financial Results
- Ramada Investimentos e Industria, S.A. (RAM.LS) Income Statement Analysis – Financial Results
- Paradigm Medical Industries, Inc. (PDMI) Income Statement Analysis – Financial Results
- Cleveland-Cliffs Inc. (CVA.DE) Income Statement Analysis – Financial Results
- Haad Thip Public Company Limited (HAATF) Income Statement Analysis – Financial Results
Monte Rosa Therapeutics, Inc. (GLUE)
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.22M | 8.56M | 2.13M | 537.00K | 72.00K |
| Gross Profit | -6.22M | -8.56M | -2.13M | -537.00K | -72.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 111.27M | 85.06M | 57.16M | 24.01M | 7.35M |
| General & Administrative | 32.04M | 27.32M | 15.73M | 4.01M | 644.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.04M | 27.32M | 15.73M | 4.01M | 644.00K |
| Other Expenses | 0.00 | 0.00 | -960.00K | -7.68M | 276.00K |
| Operating Expenses | 143.31M | 112.38M | 72.88M | 28.01M | 7.99M |
| Cost & Expenses | 143.31M | 112.38M | 72.88M | 28.01M | 7.99M |
| Interest Income | 9.33M | 3.76M | 46.00K | 9.00K | 12.00 |
| Interest Expense | 0.00 | 3.76M | 0.00 | 0.00 | 1.00K |
| Depreciation & Amortization | 6.22M | 8.56M | 2.13M | 537.00K | 72.00K |
| EBITDA | -137.09M | -99.94M | -70.75M | -27.47M | -7.67M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -143.31M | -112.38M | -72.88M | -28.01M | -7.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.30M | 3.88M | -1.08M | -7.87M | 254.00K |
| Income Before Tax | -135.01M | -108.50M | -73.96M | -35.88M | -7.74M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 338.00K | -3.88M | -2.02M | 189.00K | 277.00K |
| Net Income | -135.35M | -104.62M | -71.94M | -36.07M | -8.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| EPS Diluted | -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| Weighted Avg Shares Out | 51.40M | 47.23M | 46.54M | 44.00M | 44.00M |
| Weighted Avg Shares Out (Dil) | 51.40M | 47.23M | 46.54M | 44.00M | 44.00M |
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients Recommended...
Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 64.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an...
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at...
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 100.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an...
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.70 per share a year ago.
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice
Does Monte Rosa Therapeutics (GLUE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Monte Rosa Therapeutics (GLUE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate...
This Biotech Stock Has Doubled Its Value Today—Here's Why
Shares of Monte Rosa Therapeutics (GLUE) more than doubled Monday after the biotechnology company struck an exclusive development and commercialization license agreement with Novartis (NVS) for its treatments for immune system diseases that could be worth more than $2 billion.
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
Monte Rosa Therapeutics shares doubled Monday on a deal with Novartis to develop treatments for immune system conditions.
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications Monte Rosa to receive up-front payment of $150 million and is eligible to receive milestone payments, U.S. profit and loss share, and tiered royalties on...
Source: https://incomestatements.info
Category: Stock Reports